Introduction {#dom12424-sec-0001}
============

Teneligliptin, characterized by a considerably rigid structure formed by five consecutive rings, is a novel dipeptidyl peptidase‐4 (DPP‐4) inhibitor for the treatment of type 2 diabetes [1](#dom12424-bib-0001){ref-type="ref"}. Introduction of the 1‐(1‐phenylpyrazol‐5‐yl) piperazine moiety (anchor lock domain), which binds to the S2 extensive subsite, increased the activity by 1500‐fold over the corresponding fragment that binds to S1 and S2 only [2](#dom12424-bib-0002){ref-type="ref"}. As the metabolites of this drug are excreted through the hepatic (∼35%) and renal (∼65%) routes, no dose adjustment is necessary in patients with renal impairment [1](#dom12424-bib-0001){ref-type="ref"}. Particularly because of its long half‐life, this drug has been shown to stabilize glucose fluctuations throughout the day [3](#dom12424-bib-0003){ref-type="ref"}. We conducted the present study to confirm the efficacy and safety of teneligliptin combined with metformin in Korean patients with type 2 diabetes inadequately controlled with metformin monotherapy.

Methods {#dom12424-sec-0002}
=======

The present study was a randomized, double‐blind, placebo‐controlled, parallel‐group, phase III study, designed to confirm the efficacy and safety of teneligliptin combined with metformin. The protocol was approved by the institutional review boards at each participating site. This trial was registered with [ClinicalTrials.gov](http://ClinicalTrials.gov) (no. NCT01805830).

Patients with type 2 diabetes were eligible to participate if they had inadequate glycaemic control \[glycated haemoglobin (HbA1c) levels 7.0--10.0%\] on stable‐dose metformin monotherapy (≥1000 mg/day) for at least 8 weeks. Patients who had type 1 diabetes, current or a history of significant comorbidities, such as cardiovascular, hepatic and renal conditions, were excluded from the study. After the 2‐week run‐in period, eligible patients were assigned 2 : 1 to a 20 mg teneligliptin once daily or a placebo once daily group, respectively. The metformin dose was kept constant throughout the study period. Rescue therapy was not permitted during the study period. Patients were withdrawn from the study if they met the predefined fasting plasma glucose thresholds during any subsequent visit.

A change from baseline in patients\' HbA1c levels after 16 weeks of treatment was used as the primary efficacy endpoint. Safety and tolerability were assessed throughout the study.

Efficacy analyses were performed using the full population set (≥1 dose of study medication and baseline and post‐baseline efficacy data) with last observation carried forward methodology. The changes from baseline to week 16 were compared between the two groups using analysis of covariance, with site as a fixed effect and baseline HbA1c level as a covariate. The point estimate and the 95% confidence interval for the difference between the two groups were calculated based on the least squares mean ± standard error.

Results {#dom12424-sec-0003}
=======

Of the 317 subjects screened, 204 eligible subjects were randomized to treatment: 136 received teneligliptin plus metformin and 68 received placebo plus metformin. A total of 177 (86%) patients completed 16 weeks of treatment (Figure S1). Treatment groups were balanced with respect to demographics and disease characteristics (Table S1). The mean baseline HbA1c was 7.9% in the teneligliptin plus metformin group and 7.8% in the placebo plus metformin group. The mean metformin dose over the study period was ∼1400 mg for both treatment groups.

The adjusted mean changes from baseline values were −0.90% for the teneligliptin plus metformin group compared with −0.12% for the placebo plus metformin group (p \< 0.0001; Table [1](#dom12424-tbl-0001){ref-type="table"}). A greater decrease in HbA1c was observed in the teneligliptin plus metformin group compared with the placebo plus metformin group at week 4 and throughout the randomized treatment period (Figure [1](#dom12424-fig-0001){ref-type="fig"}). The adjusted mean change in fasting plasma glucose from baseline to week 16 was −0.93 mmol/l (16.79 mg/dl) for the teneligliptin plus metformin group versus +0.32 mmol/l (5.69 mg/dl) for the placebo plus metformin group (p \< 0.0001). A significantly greater proportion of patients achieved a therapeutic glycaemic response (HbA1c \< 7%) with teneligliptin plus metformin than with placebo plus metformin (64.71 vs. 13.24%, respectively; p \< 0.001).

###### 

Effects of teneligliptin and placebo on glucose metabolism

                                                   Teneligliptin                                      Placebo
  ------------------------------------------------ -------------------------------------------------- ------------------------------------------------
  **HbA1c, %**                                                                                        
  **Baseline**                                                                                        
  Mean (s.d.)                                      7.79 (0.80)                                        7.72 (0.65)
  **At week 16**                                                                                      
  Mean (s.d.)                                      6.93 (0.84)                                        7.65 (0.80)
  **Change from baseline to week 16**                                                                 
  Mean (s.d.)                                      −0.87 (0.65)                                       −0.06 (0.55)
  p value for within treatment group               \<0.0001[\*](#dom12424-note-0003){ref-type="fn"}   0.3384[†](#dom12424-note-0004){ref-type="fn"}
  **Difference vs. placebo**                                                                          
  Adjusted mean (s.e.)                             −0.90 (0.07)                                       −0.12 (0.09)
  Adjusted mean for difference (s.e.)              −0.78 (0.09)                                       ---
  95% CI of adjusted mean                          −0.95, −0.61                                       ---
  p value[‡](#dom12424-note-0005){ref-type="fn"}   \<0.0001                                           ---
  **FPG (mmol/l)**                                                                                    
  **Baseline**                                                                                        
  Mean (s.d.)                                      8.39 (1.97)                                        8.39 (1.43)
  **At week 16**                                                                                      
  Mean(s.d.)                                       7.47 (1.78)                                        8.71 (1.78)
  **Change from baseline to week 16**                                                                 
  Mean (s.d.)                                      −0.93 (1.37)                                       0.32 (1.44)
  p‐value for within treatment group               \<0.0001[†](#dom12424-note-0004){ref-type="fn"}    0.0749[†](#dom12424-note-0004){ref-type="fn"}
  **Difference vs. placebo**                                                                          
  Adjusted mean (s.e.)                             −1.10 (0.15)                                       0.15 (0.19)
  Adjusted mean for difference (s.e.)              −1.24 (0.18)                                       ---
  95% CI of adjusted mean                          (−1.61, −0.88)                                     ---
  p‐value[‡](#dom12424-note-0005){ref-type="fn"}   \<0.0001                                           ---
  **HOMA‐β**                                                                                          
  **Baseline**                                                                                        
  Mean (s.d.)                                      35.68 (26.15)                                      33.39 (22.47)
  **At week 16**                                                                                      
  Mean (s.d.)                                      46.89 (38.86)                                      33.57 (24.75)
  **Change from baseline to week 16**                                                                 
  Mean (s.d.)                                      11.22 (24.29)                                      0.19 (13.19)
  p value for within treatment group               \<0.0001[\*](#dom12424-note-0003){ref-type="fn"}   0.8385[\*](#dom12424-note-0003){ref-type="fn"}
  **Difference vs. placebo**                                                                          
  Adjusted mean (s.e.)                             12.76 (2.59)                                       2.17 (3.19)
  Adjusted mean for difference (s.e.)              10.59 (3.11)                                       ---
  95% CI of adjusted mean                          4.46, 16.72                                        ---
  p value[‡](#dom12424-note-0005){ref-type="fn"}   0.0008                                             ---
  **HOMA‐IR**                                                                                         
  **Baseline**                                                                                        
  Mean (s.d.)                                      3.10 (2.52)                                        2.87 (1.94)
  **At week 16**                                                                                      
  Mean (s.d.)                                      2.81 (2.27)                                        3.01 (1.93)
  **Change from baseline to week 16**                                                                 
  Mean (s.d.)                                      −0.29 (1.81)                                       0.13 (1.43)
  p value for within treatment group               0.0533[\*](#dom12424-note-0003){ref-type="fn"}     0.4430[†](#dom12424-note-0004){ref-type="fn"}
  **Difference vs. placebo**                                                                          
  Adjusted mean (s.e.)                             −0.29 (0.18)                                       0.02 (0.23)
  Adjusted mean for difference (s.e.)              −0.30 (0.22)                                       ---
  95% CI of adjusted mean                          −0.74, 0.14                                        ---
  p value[‡](#dom12424-note-0005){ref-type="fn"}   0.1754                                             ---

HbA1c, glycated haemoglobin; HOMA‐β, homeostasis model assessment of β‐cell function; HOMA‐IR, homeostasis model assessment of insulin resistance; s.d., standard deviation; s.e., standard error; CI, confidence interval.

Change from baseline (Wilcoxon signed‐rank test).

Change from baseline (paired t‐test).

Difference in change from baseline between treatment groups (analysis of covariance model included site as a fixed effect and baseline as a covariate).
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Greater increases in β‐cell function based on homeostasis model assessment of β‐cell function (HOMA‐β) were observed in patients treated with teneligliptin plus metformin compared with those treated with placebo plus metformin at week 16 (p = 0.0008). Homeostasis model assessment of insulin resistance (HOMA‐IR) showed an improving trend in patients treated with teneligliptin plus metformin compared with placebo plus metformin (p = 0.1754). No differences were observed between treatment groups in the exploratory efficacy endpoints of body weight, fasting insulin, fasting C‐peptide, high‐sensitivity C‐reactive protein or lipid variables.

Teneligliptin combined with metformin was well tolerated compared with placebo added to metformin (Table S2). All of the events were classified as mild and did not result in study discontinuation.

Discussion {#dom12424-sec-0004}
==========

The mean reduction in HbA1c level after 16 weeks of treatment with teneligliptin combined with ongoing metformin therapy was ∼0.9%, a result similar to or slightly higher than the results of previous studies performed with other DPP‐4 inhibitors [4](#dom12424-bib-0004){ref-type="ref"}, [5](#dom12424-bib-0005){ref-type="ref"}, [6](#dom12424-bib-0006){ref-type="ref"}, [7](#dom12424-bib-0007){ref-type="ref"}. A meta‐analysis by Kim et al. [7](#dom12424-bib-0007){ref-type="ref"} showed a greater blood glucose‐lowering efficacy of DPP‐4 inhibitors in Asian than in non‐Asian people. In trials evaluating oral combination therapy, the overall difference in HbA1c was −0.85% in Asian‐dominant studies (≥50% Asian participants), whereas it changed by −0.66% in non‐Asian‐dominant studies. The changes in HbA1c observed in the present study for the teneligliptin plus metformin group were similar to those achieved with the addition of teneligliptin to pioglitazone [8](#dom12424-bib-0008){ref-type="ref"} or glimepiride [9](#dom12424-bib-0009){ref-type="ref"}.

The HOMA‐β value was improved significantly by the addition of teneligliptin in the present study. HOMA‐IR values showed an improving trend after the addition of teneligliptin; however, the possibility cannot be excluded that this may have been an indirect action through the improvement in glycaemia. Pancreatic α‐cell glucagon secretion, which accelerates hepatic glucose delivery, is suppressed by DPP‐4 inhibitors [10](#dom12424-bib-0010){ref-type="ref"}. Vildagliptin significantly lowered the plasma levels of postprandial glucagon and endogenous glucose [10](#dom12424-bib-0010){ref-type="ref"}. Teneligliptin also suppressed fasting and postprandial glucagon [3](#dom12424-bib-0003){ref-type="ref"}. Teneligliptin‐induced suppression of glucagon could also be responsible for improved insulin sensitivity. No safety or tolerability concerns were observed with teneligliptin as an add‐on to metformin treatment in this study.

Although the maximum recommended daily dose for metformin is 2500 mg, the percentage of patients receiving metformin \>1500 mg/day in Korea was relatively small [11](#dom12424-bib-0011){ref-type="ref"}. We chose a dose of metformin ≥1000 mg/day. No clinically relevant interaction was observed with the co‐administration of teneligliptin with metformin because of the concurrent involvement of renal excretion and multiple metabolic pathways in its elimination [12](#dom12424-bib-0012){ref-type="ref"}.

In conclusion, the addition of teneligliptin to metformin treatment was effective and well tolerated in Korean patients with type 2 diabetes.
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